title: Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
authors.forename: A M
authors.initials: AM
authors.lastname: Fink
authors.forename: S
authors.initials: S
authors.lastname: Böttcher
authors.forename: M
authors.initials: M
authors.lastname: Ritgen
authors.forename: K
authors.initials: K
authors.lastname: Fischer
authors.forename: N
authors.initials: N
authors.lastname: Pflug
authors.forename: B
authors.initials: B
authors.lastname: Eichhorst
authors.forename: C-M
authors.initials: CM
authors.lastname: Wendtner
authors.forename: D
authors.initials: D
authors.lastname: Winkler
authors.forename: A
authors.initials: A
authors.lastname: Bühler
authors.forename: T
authors.initials: T
authors.lastname: Zenz
authors.forename: P
authors.initials: P
authors.lastname: Staib
authors.forename: J
authors.initials: J
authors.lastname: Mayer
authors.forename: M
authors.initials: M
authors.lastname: Hensel
authors.forename: G
authors.initials: G
authors.lastname: Hopfinger
authors.forename: M
authors.initials: M
authors.lastname: Wenger
authors.forename: G
authors.initials: G
authors.lastname: Fingerle-Rowson
authors.forename: H
authors.initials: H
authors.lastname: Döhner
authors.forename: M
authors.initials: M
authors.lastname: Kneba
authors.forename: S
authors.initials: S
authors.lastname: Stilgenbauer
authors.forename: R
authors.initials: R
authors.lastname: Busch
authors.forename: M
authors.initials: M
authors.lastname: Hallek
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D018450:Disease Progression; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000069283:Rituximab; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine